The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
 
Tiffany A. Traina
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Exact Sciences; G1 Therapeutics; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Merck; Pfizer; Stemline Therapeutics; Tersera
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Pfizer (Inst)
 
Yuan Chen
No Relationships to Disclose
 
Katia Khoury
No Relationships to Disclose
 
Hope S. Rugo
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)
 
Erica L. Mayer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis
 
Lisa A. Carey
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Veracyte (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly; Novartis (Inst); SeaGen
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Speakers' Bureau - AstraZeneca (I); Genentech (I); Gilead Sciences (I)
Research Funding - DAEHWA Pharmaceutical (Inst); Novartis (Inst); OBI Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
Expert Testimony - GlaxoSmithKline
 
Angemael Syldor
No Relationships to Disclose
 
Chaya Friedman
No Relationships to Disclose
 
Jennifer Savoie
No Relationships to Disclose
 
Fresia Pareja
Consulting or Advisory Role - AstraZeneca; MultiplexDx
 
Britta Weigelt
Employment - AstraZeneca (I)
Stock and Other Ownership Interests - Repare Therapeutics (I)
Consulting or Advisory Role - Bain Capital Life Sciences (I); Goldman Sachs (I); PAIGE (I); Repare Therapeutics (I); SAGA Diagnostics (I); Volition RX (I)
Research Funding - Repare Therapeutics
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Odyssey Biosciences; Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Boxer Capital; Inivata; Lilly; Novartis; Paige.ai; Prelude Therapeutics; SAGA Diagnostics; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Paige.ai (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Novartis Institutes for BioMedical Research
Other Relationship - Peerview; Targeted Oncology; WebMD
(OPTIONAL) Uncompensated Relationships - Odyssey Biosciences; Totus Medicines
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Guardant Health; Inivata; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Relay Therapeutics; Repare Therapeutics; Roche
Research Funding - AstraZeneca (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Merck Sharpe and Dohme (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)
 
Suzanne D. Conzen
Patents, Royalties, Other Intellectual Property - A GR antagonist methods patent owned by the University of Chicago that I am a co-Inventor on is licensed to Corcept Therapeutics
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exact Sciences; GE Healthcare; Gilead Sciences; Guardant Health; Merck; Moderna Therapeutics; Novartis; Sanofi; Seagen; Stemline Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics